Changes in Cognition During a 24-h Simulated Military Operation
Primary Purpose
Cognitive Impairment
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
beta-alanine
placebo
Sponsored by

About this trial
This is an interventional other trial for Cognitive Impairment focused on measuring beta-alanine, immune cells
Eligibility Criteria
Inclusion Criteria:
- Participants in this study will be males aged 18-35, preferably with military training or are current Reserve Officers' Training Corps cadets
- Free of any physical limitations (determined by medical and activity history questionnaire [MHQ] and the physical activity readiness questionnaire [PAR-Q+]).
- Participants will be required to be recreationally-active (defined according to American College of Sports Medicine standards of at least 150 minutes exercise per week).
- Participants must be willing abstain from dietary supplementation throughout the duration of the study.
- Participant understands the study procedures and signs forms providing informed consent to participate in the study.
Exclusion Criteria:
- Individual does not provide consent to participate in this study.
- Inability to perform physical exercise (determined by health and activity questionnaire [MHQ] and physical activity readiness questionnaire [PAR-Q+]). That is Answering "Yes" to any question on the PAR-Q+, or having a pre-existing condition such as musculoskeletal injury, back pain, chronic pain etc. that the investigative team perceives will prevent a participant from safely completing the protocol.
- Taking any other nutritional supplement or performance-enhancing drug (determined from health and activity questionnaire).
- Regularly taking any type of prescription or over-the-counter medication, or having any chronic illnesses, which require medical care.
- Inability to complete any of the exercise performance testing on the familiarization day.
Sites / Locations
- Kinesiology Research Labs
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Beta-alanine
Placebo
Arm Description
4 g by mouth, 3 times per day with regular meals for 14 days.
4 g by mouth, 3 times per day with regular meals for 14 days.
Outcomes
Primary Outcome Measures
Symptoms checklist
monitor frequency and severity of subjective symptoms related to a broad spectrum of conditions. The participant is presented with 21 symptoms. The participant is required to rate each symptom (e.g. fatigue, headache, Nausea, numbness/tingling etc. on a scale from 0 (Not Present) to 6 (Severe)
COGcomp (composite measure of cognition)
Throughput (TP) scores from each of seven cognitive assessments administered as part of a battery of tests via Automated Neuropsychological Assessment Metrics (ANAM) computer software. Tests include:
Simple reaction time
Code Substitution
Procedural Reaction Time
Mathematical processing
Matching to sample
Code substitution Delayed
Simple reaction time repeat
Monocyte chemoattractant protein-1 (MCP-1)
Serum concentrations of MCP-1
Macrophage-1-antigen (CD11b)
Surface expression of CD11b on classical monocytes and neutrophils
C-C chemokine receptor 2 (CCR2)
Surface expression of CCR2 on classical monocytes
Interleukin-8
Serum concentrations of interleukin-8
Lymphocyte function-associated antigen-1 (CD11a)
Surface expression of CD11a on classical monocytes and neutrophils
Secondary Outcome Measures
Full Information
NCT ID
NCT04250480
First Posted
January 29, 2020
Last Updated
January 30, 2020
Sponsor
University of Central Florida
Collaborators
National Strength and Conditioning Foundation
1. Study Identification
Unique Protocol Identification Number
NCT04250480
Brief Title
Changes in Cognition During a 24-h Simulated Military Operation
Official Title
Changes in Cognition During a 24-h Simulated Military Operation (SUSOP). Influence of β-alanine Supplementation and Markers of Classical Monocyte Recruitment
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
October 2, 2017 (Actual)
Primary Completion Date
April 15, 2018 (Actual)
Study Completion Date
April 15, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Central Florida
Collaborators
National Strength and Conditioning Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Sustained military operations (SUSOPs) result in psychological stress and cognitive dysfunction, which may be related to the recruitment of classical monocytes into the brain.
Goals:
To investigate the effect of sustained-release beta-alanine on changes in cognition and markers of immune cell recruitment during a 24-hour simulated military operation.
To examine associations between changes cognition and changes in markers mediating immune cell recruitment.
Detailed Description
Sustained military operations (SUSOPs) expose soldiers to a multitude of stressors, including sustained physical activity, caloric deficit, and sleep deprivation. Several studies have shown that the combination of these factors result in psychological stress, which often leads to significant cognitive impairment.
Psychological stress has been shown to result in activation of neuroendocrine pathways that signal into the periphery and relay information from the brain to the immune system. This process is generally characterized by elevations of several key pro-inflammatory cytokines, chemokines, secondary messengers and reactive oxygen species. Notably, peripheral classical monocytes are reported to undergo recruitment to the brain during periods of psychological stress following priming by cytokines secreted from activated microglia.
Carnosine, an endogenous dipeptide consisting of beta-alanine and L-histidine, has been shown to inhibit the synthesis of inflammatory and oxidative mediators in microglia in vitro. Beta-alanine, which is the rate limiting amino acid in carnosine formation has been shown to increase carnosine concentrations in various regions of the brain in rodents which been associated with biochemical changes that resulted in favorable improvements in resilience to stress exposure. However, data on the effects of beta-alanine supplementation on cognition in humans is less clear. Further, the effect of beta-alanine supplementation on systemic and cellular mediators of monocyte recruitment has not been examined.
Goals:
To investigate the effect of sustained-release beta-alanine on changes in psychological stress and cognition using Automated Neuropsychological Assessment Metric (ANAM) cognitive assessments during a 24-hour simulated military operation.
To examine the effect of sustained-release beta-alanine on monocyte chemoattractant protein-1 (MCP-1), interleukin-8, Lymphocyte function-associated antigen-1 (CD11a), macrophage-1-antigen (CD11b) expression and C-C chemokine receptor 2 (CCR2) expression on neutrophils and classical monocytes during a 24-hour simulated military operation.
To examine associations between MCP-1, interleukin-8, CD11a, CD11b, CCR2 and a composite measure of cognition derived from ANAM assessment scores during a 24-hour simulated military operation.
Method:
Double-blind placebo controlled trial compared the effect of supplementation with sustained release beta-alanine (12 grams per day) versus placebo (equivalent amount of rice powder) on cognition and monocyte responses during a 24-hour simulated military operation consisting of sleep-restriction, caloric restriction, and acute and sustained periods military specific physical activity.
Supplementation occurred over a period of 14 days prior to completion of the simulated military operation. ANAM tests were assessed and blood samples taken upon arrival to the lab for the 24 hour simulated operation (0 hours) and at 12, 18 and 24 hours during the SUSOP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Impairment
Keywords
beta-alanine, immune cells
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Beta-alanine
Arm Type
Experimental
Arm Description
4 g by mouth, 3 times per day with regular meals for 14 days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
4 g by mouth, 3 times per day with regular meals for 14 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
beta-alanine
Intervention Description
beta-alanine tablet
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Intervention Description
rice powder tablet
Primary Outcome Measure Information:
Title
Symptoms checklist
Description
monitor frequency and severity of subjective symptoms related to a broad spectrum of conditions. The participant is presented with 21 symptoms. The participant is required to rate each symptom (e.g. fatigue, headache, Nausea, numbness/tingling etc. on a scale from 0 (Not Present) to 6 (Severe)
Time Frame
Change from 0 at 12, 18 and 24 hours
Title
COGcomp (composite measure of cognition)
Description
Throughput (TP) scores from each of seven cognitive assessments administered as part of a battery of tests via Automated Neuropsychological Assessment Metrics (ANAM) computer software. Tests include:
Simple reaction time
Code Substitution
Procedural Reaction Time
Mathematical processing
Matching to sample
Code substitution Delayed
Simple reaction time repeat
Time Frame
Change from 0 at 12, 18 and 24 hours
Title
Monocyte chemoattractant protein-1 (MCP-1)
Description
Serum concentrations of MCP-1
Time Frame
Change from 0 at 12, 18 and 24 hours
Title
Macrophage-1-antigen (CD11b)
Description
Surface expression of CD11b on classical monocytes and neutrophils
Time Frame
Change from 0 at 12, 18 and 24 hours
Title
C-C chemokine receptor 2 (CCR2)
Description
Surface expression of CCR2 on classical monocytes
Time Frame
Change from 0 at 12, 18 and 24 hours
Title
Interleukin-8
Description
Serum concentrations of interleukin-8
Time Frame
Change from 0 at 12, 18 and 24 hours
Title
Lymphocyte function-associated antigen-1 (CD11a)
Description
Surface expression of CD11a on classical monocytes and neutrophils
Time Frame
Change from 0 at 12, 18 and 24 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Participants in this study will be males aged 18-35, preferably with military training or are current Reserve Officers' Training Corps cadets
Free of any physical limitations (determined by medical and activity history questionnaire [MHQ] and the physical activity readiness questionnaire [PAR-Q+]).
Participants will be required to be recreationally-active (defined according to American College of Sports Medicine standards of at least 150 minutes exercise per week).
Participants must be willing abstain from dietary supplementation throughout the duration of the study.
Participant understands the study procedures and signs forms providing informed consent to participate in the study.
Exclusion Criteria:
Individual does not provide consent to participate in this study.
Inability to perform physical exercise (determined by health and activity questionnaire [MHQ] and physical activity readiness questionnaire [PAR-Q+]). That is Answering "Yes" to any question on the PAR-Q+, or having a pre-existing condition such as musculoskeletal injury, back pain, chronic pain etc. that the investigative team perceives will prevent a participant from safely completing the protocol.
Taking any other nutritional supplement or performance-enhancing drug (determined from health and activity questionnaire).
Regularly taking any type of prescription or over-the-counter medication, or having any chronic illnesses, which require medical care.
Inability to complete any of the exercise performance testing on the familiarization day.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adam J Wells, PhD
Organizational Affiliation
University of Central Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kinesiology Research Labs
City
Orlando
State/Province
Florida
ZIP/Postal Code
32816
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Changes in Cognition During a 24-h Simulated Military Operation
We'll reach out to this number within 24 hrs